Leonard Zehr - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Leonard Zehr's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Leonard Zehr
Verified
Editor, biotuesdays.com
Windsor
Beats
Business And Finance , Banks , Consumer Finance
Non
Content
By Leonard Zehr| biotuesdays.com@ Leonard ZehrKorro Bio’s reverse merger with Frequency Therapeutics (NASDAQ:FREQ), which is expected to close in the 2023 fourth quarter, and concurrent financing are expected to build up an investor base to bankroll Korro’s proprietary platform, OPERA, for RNA editing with the potential to functionally repair genetic mutations transiently, as well as create de novo mutations to alleviate clinical pathology.
By Leonard Zehr| biotuesdays.com@ Leonard ZehrKorro Bio’s reverse merger with Frequency Therapeutics (NASDAQ:FREQ), which is expected to close in the 2023 fourth quarter, and concurrent financing are expected to build up an investor base to bankroll Korro’s proprietary platform, OPERA, for RNA editing with the potential to functionally repair genetic mutations transiently, as well as create de novo mutations to alleviate clinical pathology.
By Leonard Zehr| biotuesdays.com@ MIRA Pharmaceuticals (NASDAQ:MIRA) is developing MIRA1a, a novel synthetic analog of THC (tetrahydrocannabinol) to treat anxiety and cognitive decline in the elderly and neuropathic pain, with a lower impurity profile and the potential to have fewer side effects than cannabis plant extracts. “These three therapeutic areas represent high disease burden and significant unmet needs,” Erez Aminov, CEO of MIRA, says in an interview with BioTuesdays.
Company Info
biotuesdays.com
BioTuesdays is a company dedicated to delivering news and insights in the healthcare industry, with a particular emphasis on biotechnology. Founded in 2009 by Kilmer Lucas, it operates from Cambridge, Ontario, Canada. The company serves as a resource for individuals interested in the latest developments in the biotech and pharmaceutical sectors. The primary offering of BioTuesdays is its content, which includes news articles, market updates, and analysis on corporate and clinical developments, executive changes, and market trends. The platform caters to a diverse audience, including investors, researchers, and industry professionals, who seek to stay informed about advancements in healthcare. Despite being a smaller operation, BioTuesdays provides valuable insights into breakthrough therapies and market developments within the healthcare sector.
'+1 905-486-1158
Founded: 2009